Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets
Advertisement

Related Content

As Speculation Mounts In Korea, Biosimilar Play Celltrion Still Seems Likely To Sell To Big Pharma
Korea’s Samsung Biologics Halts Rituxan Biosimilar Trials To Meet U.S, EU Standards
Korea’s Samsung And Biogen Idec Initiate JV For Global Biosimilars Development
Green Cross Banking On Bioreactors To Develop Biosimilars, Biobetters Faster
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
Samsung Biologics Takes First Step In The CMO Business While Targeting Innovative Compounds By 2017
Korea FDA OKs Samsung's Clinical Trial Application For Roche's MabThera Biosimilar
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
Advertisement
UsernamePublicRestriction

Register

SC078331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel